Neuromuscular blockade, which is used by anesthesiologists to relax muscles during surgery, is revered by the sugammadex sodium injection. Upon approval, this substance would be one of the first medicines of its kind to be used in the U.S. surgical setting.
The FDA previously rejected the NDA in 2008 and requested more data on allergic reactions and bleeding events. The application has now been deemed complete for review.
More Articles on Anesthesia:
CMS Updates Locale Specific Anesthesia Conversion Rate
Novitas Expected to Revise Anesthesia Coverage Limits
Providence Washington Anesthesia Services Announces CME Symposium, Proceeds to Benefit Non-Profit
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
